Nanochap Secures Over RMB 100 Million in Series B1 Funding to Advance Biochip and Neural Interface Innovations

PE Daily (ID: pedaily2012) reported on September 30 that recently,Nanochap(Nanochap) announces completionOver RMB 100 Million Series B1Financing, byTaiyue CapitalLead investor,Skytrace Capital、Zhaorui Investment、Dandelion...and other institutions co-invested. It is reported that the funds from this round will primarily be used forFurther investment in R&D, team building, and business expansionetc.

Public records show that Nanochap Electronics Co., Ltd., established in 2014, is aHigh-Tech Biochip R&D Enterprise, by the StateThousand Talents Plan Expert、National Key Research and Development Program ProjectChief Scientist Dr. Yang JiaweiFounded with its headquarters in Hangzhou Future Sci-Tech City, the company has established R&D centers in Australia and Vietnam, while its East China (Shanghai) and Southern Zhejiang (Wenzhou) R&D centers are currently under construction. It is understood that Nanochap is dedicated to the development and application of cutting-edge technologies, including ultra-high-density brain-computer neural interfaces, neural stimulation chips, and bio-microsignal sensing chips. After years of technological accumulation and innovation, Nanochap has successfully completed the research and development of multiple internationally leading products.

Among them,One application of ultra-high-density brain-computer neural interfaces—the high-resolution artificial retina—is currently the world's highest-resolution artificial vision technology (320 independent stimulation channels)., it can restore functional vision in blind individuals or patients with central vision loss. It utilizes an externally worn device to convert real-time image signals into neural electrical signals, which are then wirelessly transmitted to a high-density stimulation chip implanted within the eye. Finally, through an electrode array connected to the chip, the signals are relayed via the visual pathway to the cerebral cortex to reconstruct images. This project has been selected for the National Key R&D Program, with all technical specifications ranking at the international forefront. The production line has been completed, and the system is poised to enter the clinical trial phase.

It is worth mentioning that the multifunctional stimulation chip hasCommercial Usein neuromodulation-based pain relief products and muscle repair products. Meanwhile, the company has developed a programmable universal neural stimulation chip, which is the world's only multi-channel stimulation chip that allows for the arbitrary configuration of stimulation parameters and waveforms via programming, and is applicable to all types of neural stimulators.

It is reported that the biomolecular signal processing chip series can detect extremely weak biomolecular signals in body fluids such as sweat, saliva, and urine in real time, including uric acid, lactic acid, glucose, electrolytes, cortisol, and cholesterol. Currently, this technology is capable of detecting signals as low as the μV/pA level, demonstrating significant application prospects in cutting-edge fields such as the high-throughput detection of neuronal action potentials and nucleotide base signals.

In the future, Nanochap will continue toNeural Interface and BiosensingDeepening R&D in these and related areas, consolidating the technological foundation, accelerating the commercialization of multiple technologies, and actively enriching the product portfolio to expand into more applications. Nanochap's professional-grade, low-cost biochips will provide reliable solutions not only for professional medical institutions but also for a broader range of life and health products.